Joshua A. Jacobs

Joshua A. Jacobs, PhD, PharmD

Academic Information

Departments Adjunct - Pharmacotherapy

Board Certification

  • Board of Pharmacy Specialties (Sub: Cardiology Pharmacy)

Education History

Doctoral Training University of Utah Spencer Fox Eccles School of Medicine
 PhD
Residency Ohio State University Wexner Medical Center
 Resident
Residency Intermountain Medical Center
 Resident
Professional Medical University of Toledo College of Pharmacy and Pharmaceutical Sciences
 PharmD
Undergraduate University of Toledo College of Pharmacy and Pharmaceutical Sciences
 BPharm

Selected Publications

Journal Article

  1. Zheutlin AR, Jacobs JA, Bress AP (2025). High-Density Lipoprotein Cholesterol and Statin Use Among U.S. Adults With Intermediate 10-Year Predicted ASCVD Risk. JACC Adv, 4(6 Pt 2), 101725. (Read full article)
  2. Bullock G, Jacobs JA, Carey JR, Pan IZ, Kinsey MS, Sideris K, Kapelios CJ, Stehlik J, Fang JC, Das S, Carter SJ (2024). Patterns of diuretic titration during inpatient management of acute decompensated heart failure. Am Heart J, 282, 30-39. (Read full article)
  3. Cintron MA, Baumer Y, Pang APS, Aquino Peterson EM, Ortiz-Whittingham LR, Jacobs JA, Sharda S, Potharaju KA, Baez AS, Gutierrez-Huerta CA, Ortiz-Chaparro EN, Collins BS, Mitchell VM, Saurabh A, Mendelsohn LG, Redekar NR, Paul S, Corley MJ, Powell-Wiley TM (2025). Associations between the neural-hematopoietic-inflammatory axis and DNA methylation of stress-related genes in human leukocytes: Data from the Washington, D.C. cardiovascular health and needs assessment. Brain Behav Immun Health, 45, 100976. (Read full article)
  4. Zheutlin AR, Jacobs JA, Niforatos JD, Chaitoff A (2025). Prevalence of prescription medication use that can exacerbate heart failure among US adults with heart failure. Pharmacotherapy, 45(3), 155-160. (Read full article)
  5. Jacobs JA, Ayodele I, Bress AP, Sterling MR, Pandey A, Derington CG, Zheutlin AR, Shah KS, Greene SJ, Alhanti B, Blanco R, Fonarow GC (2024). Social Determinants of Health and Disparities in Guideline-Directed Medical Therapy Optimization for Heart Failure. Circ Heart Fail, 18(1), e012357. (Read full article)
  6. Jacobs JA, Rodgers A, Bellows BK, Hernandez I, Wang N, Derington CG, King JB, Zheutlin AR, Whelton PK, Egan BM, Cushman WC, Bress AP (2024). Use and Cost Patterns of Antihypertensive Medications in the United States From 1996 to 2021. Hypertension, 81(11), 2307-2317. (Read full article)
  7. Zheutlin AR, Jacobs JA, Stamm B, Royan R (2024). Lipoprotein(a) among normotensive patients and risk of incident hypertension. J Clin Hypertens (Greenwich), 26(11), 1313-1317. (Read full article)
  8. Xu Y, Derington CG, Addo DK, He T, Jacobs JA, Mohanty AF, An J, Cushman WC, Ho PM, Bellows BK, Cohen JB, Bress AP (2024). Trends in Initial Antihypertensive Medication Prescribing Among >2.8 Million Veterans Newly Diagnosed With Hypertension, 2000 to 2019. J Am Heart Assoc, 13(20), e036557. (Read full article)
  9. Jacobs JA, Carter SJ, Bullock G, Carey JR, Pan IZ, Kinsey MS, Zheutlin AR, Kapelios CJ, Raju S, Fang JC, Shah KS, Bress AP (2024). Optimal Initial Intravenous Loop Diuretic Dosing in Acute Decompensated Heart Failure. JACC Adv, 3(10), 101250. (Read full article)
  10. Mentias A, Keshvani N, Sumarsono A, Desai R, Khan MS, Menon V, Hsich E, Bress AP, Jacobs J, Vasan RS, Fonarow GC, Pandey A (2023). Patterns, Prognostic Implications, and Rural-Urban Disparities in Optimal GDMT Following HFrEF Diagnosis Among Medicare Beneficiaries. JACC Heart Fail, 12(6), 1044-1055. (Read full article)
  11. Zheutlin AR, Sharareh N, Guadamuz JS, Berchie RO, Derington CG, Jacobs JA, Mondesir FL, Alexander GC, Levitan EB, Safford M, Vos RO, Qato DM, Bress AP (2024). Association Between Pharmacy Proximity With Cardiovascular Medication Use and Risk Factor Control in the United States. J Am Heart Assoc, 13(5), e031717. (Read full article)
  12. Jacobs JA, Derington CG, Zheutlin AR, King JB, Cohen JB, Bucheit J, Kronish IM, Addo DK, Morisky DE, Greene TH, Bress AP (2024). Association Between Self-Reported Medication Adherence and Therapeutic Inertia in Hypertension: A Secondary Analysis of SPRINT (Systolic Blood Pressure Intervention Trial). J Am Heart Assoc, 13(3), e031574. (Read full article)
  13. Jacobs JA, Zheutlin AR, Derington CG, King JB, Pandey A, Bress AP (2023). Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015-2020. Am J Prev Cardiol, 17, 100624. (Read full article)
  14. Clark JL, Jacobs JA, Watanabe AH, Catino AB, Dechand JA (2023). Evaluation of Safety and Efficacy of Intravenous Digoxin Loading Doses Based on Ideal Body Weight. Ann Pharmacother, 57(10), 1154-1161. (Read full article)
  15. King JB, Berchie RO, Derington CG, Marcum ZA, Scharfstein DO, Greene TH, Herrick JS, Jacobs JA, Zheutlin AR, Bress AP, Cohen JB (2023). New Users of Angiotensin II Receptor Blocker-Versus Angiotensin-Converting Enzyme Inhibitor-Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD-BP and SPRINT. J Am Heart Assoc, 12(17), e030311. (Read full article)
  16. Zheutlin AR, Jacobs JA, Derington CG, Chaitoff A, Navar AM, Bress AP (2023). Age-based disparities in statin use for primary prevention in US adults: National Health and Nutrition Examination Surveys 2013-2020. J Clin Lipidol, 17(5), 688-693. (Read full article)
  17. King JB, Derington CG, Herrick JS, Jacobs JA, Zheutlin AR, Conroy MB, Cushman WC, Bress AP (2023). Single-Pill Combination Product Availability of the Antihypertensive Regimens Used for Intensive Systolic Blood Pressure Treatment in the Systolic Blood Pressure Intervention Trial. Hypertension, 80(8), 1749-1758. (Read full article)
  18. Zheutlin AR, Addo DK, Jacobs JA, Derington CG, Herrick JS, Greene T, Stulberg EL, Berlowitz DR, Williamson JD, Pajewski NM, Supiano MA, Bress AP (2023). Evidence for Age Bias Contributing to Therapeutic Inertia in Blood Pressure Management: A Secondary Analysis of SPRINT. Hypertension, 80(7), 1484-1493. (Read full article)
  19. Derington CG, Bress AP, Herrick JS, Jacobs JA, Zheutlin AR, Berchie RO, Conroy MB, Cushman WC, King JB (2023). Antihypertensive Medication Regimens Used by US Adults With Hypertension and the Potential for Fixed-Dose Combination Products: The National Health and Nutrition Examination Surveys 2015 to 2020. J Am Heart Assoc, 12(11), e028573. (Read full article)
  20. Jacobs JA, Addo DK, Zheutlin AR, Derington CG, Essien UR, Navar AM, Hernandez I, Lloyd-Jones DM, King JB, Rao S, Herrick JS, Bress AP, Pandey A (2023). Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020. JAMA Cardiol, 8(5), 443-452. (Read full article)
  21. Cisowska T, Pan IZ, Biskupiak J, Shah KS, Fang JC, Jacobs JA (2022). Metolazone Versus Intravenous Chlorothiazide for Decompensated Heart Failure Sequential Nephron Blockade: A Retrospective Cohort Study. J Card Fail, 28(8), 1367-1371. (Read full article)
  22. Jacobs JA, Pickworth K, Boudoulas KD, Hinkley M, McLaughlin E, Blais D (2018). Outcomes for Cancer Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Cardiovasc Revasc Med, 20(8), 711-715. (Read full article)

Review

  1. Todd OM, Knight M, Jacobs JA, Derington CG, Sheppard JP, Bress AP (2024). Pharmacologic Treatment of Hypertension in Older Adults. [Review]. Clin Geriatr Med, 40(4), 629-644. (Read full article)
  2. Osei Baah F, Sharda S, Davidow K, Jackson S, Kernizan D, Jacobs JA, Baumer Y, Schultz CL, Baker-Smith CM, Powell-Wiley TM (2024). Social Determinants of Health in Cardio-Oncology: Multi-Level Strategies to Overcome Disparities in Care: JACC: CardioOncology State-of-the-Art Review. [Review]. JACC CardioOncol, 6(3), 331-346. (Read full article)
  3. Jacobs JA, Shah RU, Bress AP (2022). Asymptomatic hypertension in the hospital setting: primum non nocere. [Review]. J Hum Hypertens, 36(9), 781-784. (Read full article)
  4. Jacobs JA, Jahangir E, Ryan JJ (2022). Differentiating pulmonary hypertension associated with protein kinase inhibitors. [Review]. Pulm Circ, 12(2), e12075. (Read full article)
  5. Mayeux JD, Pan IZ, Dechand J, Jacobs JA, Jones TL, McKellar SH, Beck E, Hatton ND, Ryan JJ (2020). Management of Pulmonary Arterial Hypertension. [Review]. Curr Cardiovasc Risk Rep, 15(1), 2. (Read full article)
  6. Pickworth KK, Blais D, Bagnola A, Barcelona R, Boyd JM, Brink H, Chilbert M, Galipeau D, Gengler B, Gerlach AT, Hayes C, Jacobs J, Kazmi H, Lavelle R, Lindsley J, Macaulay TE, Militello MA, Orzel L, Patel S, Simone P, Tasca K, Varnado S, Zoubek S (2020). COVID-19 pandemic: Challenges and solutions from the cardiology pharmacist's perspective. [Review]. J Am Coll Clin Pharm, 3(6), 1138-1146. (Read full article)
  7. Pan IZ, Carey JR, Jacobs JA, Dechand J, Sessions JJ, Sorensen T, Penn BA, Mayeux JD, Hatton ND, Ryan JJ (2020). Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension. [Review]. Front Med (Lausanne), 7, 81. (Read full article)

Commentary

  1. Jacobs JA, Ryan JJ (2020). Clinical uncertainty for the use of rivaroxaban in obesity. J Thromb Haemost, 19(3), 870-871. (Read full article)

Case Report

  1. Burkey BW, Jacobs JA, Aziz H (2017). Temperature Instability in an Infant Treated with Propranolol for Infantile Hemangioma. J Pediatr Pharmacol Ther, 22(2), 124-127. (Read full article)